Latest Dopamine agonists Stories
Parents of young caffeine consumers take heed: that high-calorie energy drink or soda might present more than just obesity risk.
BRUSSELS, June 10, 2011 /PRNewswire/ -- Results from new post hoc analyses assessing the effects of NeuproÂ® (rotigotine transdermal system) in Restless Legs Syndrome (RLS) and utilizing novel surrogate markers suggested improved daytime functioning and daytime symptoms, reduced RLS-related pain and improved mood and depressive symptoms in patients with moderate to severe RLS.
BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used NeuproÂ® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life.
ABBOTT PARK, Ill., June 9, 2011 /PRNewswire/ --Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.
Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction â€” one of the most serious drug abuse problems in the U.S.
BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that NeuproÂ® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation.
BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep.
Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinsonâ€™s disease.
- The act of lurking; skulking about; hiding; keeping from sight.